Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AIM ImmunoTech ( (AIM) ) has shared an announcement.
On April 10, 2026, AIM ImmunoTech Inc. amended its existing Equity Distribution Agreement with Maxim Group LLC, which had previously capped at-the-market sales of its common stock at $3 million. The amendment removes that cap, allowing the company to sell an unlimited amount of shares over time through Maxim as its exclusive sales agent under an effective shelf registration.
The company is also filing an updated prospectus supplement with the Securities and Exchange Commission to reflect the increased capacity for share sales in the at-the-market offering. This move expands AIM ImmunoTech’s flexibility to raise additional equity capital, which could affect its funding strategy, shareholder dilution and overall financial position going forward.
The most recent analyst rating on (AIM) stock is a Hold with a $0.53 price target. To see the full list of analyst forecasts on AIM ImmunoTech stock, see the AIM Stock Forecast page.
Spark’s Take on AIM Stock
According to Spark, TipRanks’ AI Analyst, AIM is a Neutral.
The score is driven primarily by weak financial performance—minimal and shrinking revenue, large ongoing losses, persistent cash burn, and pressured balance-sheet resilience—suggesting continued reliance on external funding. Technicals are also bearish with the stock below major moving averages and negative MACD, though oversold readings provide only limited support. Recent financing modestly improves near-term liquidity, but ongoing development and funding risks remain significant.
To see Spark’s full report on AIM stock, click here.
More about AIM ImmunoTech
AIM ImmunoTech Inc. is a biotechnology company focused on developing immunotherapeutic products, with its primary activities centered on the research, development and commercialization of treatments that modulate the immune system. The company accesses capital markets through equity offerings to support its operations and advance its pipeline of immune-focused therapies.
Average Trading Volume: 4,565,558
Technical Sentiment Signal: Strong Sell
Current Market Cap: $4.22M
Find detailed analytics on AIM stock on TipRanks’ Stock Analysis page.